We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Santarus and Cosmo Technologies have sued Actavis charging its Paragraph IV ANDA against Santarus’ ulcerative colitis therapy Uceris infringes the drug’s patents. Read More
Novartis has agreed to divest all of its BRAF and MEK inhibitor drug assets in order to move forward with its $16 billion acquisition of GlaxoSmithKline’s oncology portfolio. Read More
The branded version of Gilead’s pricey blockbuster hepatitis C therapy Sovaldi is expected on Indian pharmacy shelves in the second quarter of this year, distributed under an exclusive licensing agreement with Mylan’s Indian subsidiary. Read More
AstraZeneca will shell out $7.9 million to settle a lawsuit alleging it paid a pharmacy benefit manager to include its blockbuster heartburn drug Nexium on some formularies at the exclusion of other heartburn medications. Read More
Five Industry groups are jointly launching a new data center, the European Medicines Verification Organization, to help eliminate counterfeit drugs from the drug supply chain. Read More